test

Iris Isufi MD

Assistant Professor of Medicine (Hematology)

Clinical Interests

Bone Marrow Transplant; Stem Cell Transplant; Non-Hodgkin Lymphoma; Hodgkin Lymphoma; Multiple Myeloma


Board Certifications

Hematology (Internal Medicine), Board Eligible
2007
Internal Medicine, Board Certified
2011
Medical Oncology, Board Certified

Patient Care Locations

iris_isufifaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Limited-stage Diffuse Large B-Cell Lymphoma and Non-Hodgkin's LymphomaA Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (SWOG S1001)
Myeloid and Monocytic LeukemiaA Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Non-Hodgkin's LymphomaA randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30- positive mature T-cell lymphomas
Lymphoid LeukemiaE1912: A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Leukemia, otherA Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (=65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

More Clinical Trials...

Edit Profile